A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Back

HFA Premium Access

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Session: Late breaking clinical trials: medical therapy

Topic: Pharmacotherapy

Speaker: Professor J. Udelson (Boston, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor James E Udelson

Tufts Medical Center, Inc., Boston (United States of America)

7 presentations

0 follower

9 more presentations in this session

A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure

Speaker: Professor C. Lam (Singapore, SG)

Access

Slides

Video

Discussant review - MIRACLE

Speaker: Professor M. Packer (Dallas, US)

Access

Slides

Video

Discussant review - CARDINAL HF

Speaker: Associate Professor A. Bohm (Bratislava, SK)

Access

Slides

Video

Readily available urinary sodium analysis in patients with acute decompensate Heart Failure

Speaker: Doctor E. Meekers (Genk, BE)

Access

Slides

Video

Discussant review - EASY-HF

Speaker: Doctor P. Pellicori (Glasgow, GB)

Access

Slides

Video

Access the full session

Late breaking clinical trials: medical therapy

Speakers: Professor J. Udelson, Professor C. Lam, Professor M. Packer, Associate Professor A. Bohm, Doctor E. Meekers...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure

11 May 2024

HFA Premium Access

Discussant review - CARDINAL HF

11 May 2024

HFA Premium Access

Late breaking clinical trials: medical therapy

11 May 2024

ESC 365 is supported by

Explore sponsored resources

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

About the speaker

Professor James E Udelson

9 more presentations in this session

A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure

Discussant review - MIRACLE

Discussant review - CARDINAL HF

Readily available urinary sodium analysis in patients with acute decompensate Heart Failure

Discussant review - EASY-HF

Access the full session

Late breaking clinical trials: medical therapy

About the event

Heart Failure 2024

Related content

A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure

Discussant review - CARDINAL HF

Late breaking clinical trials: medical therapy

ESC 365 is supported by